Alumis Incis A Clinical Stage Biopharmaceutical Company Based In South San Franciscocaliforniafounded In 2021Alumis Focuses On Developing Innovative Oral Therapies For Immune Mediated Diseasesthe Company Employs A Precision Approach To Drug Developmentutilizing Its Proprietary Data Analytics Platform To Optimize Clinical Outcomes And Identify Effective Treatment Molecules Alumislead Product Candidate Is Esk 001An Oral Small Molecule Designed To Inhibit Tyrosine Kinase 2Tyk2 Currently Being Evaluated For Moderate To Severe Plaque Psoriasis And Systemic Lupus Erythematosusadditionallythe Company Is Developing A 005A Cns Penetrant Tyk2 Inhibitor Aimed At Treating Neuroinflammatory And Neurodegenerative Diseasesalumis Has Also Identified Further Preclinical Programs Through Its Precision Analytics Platform In A Significant Developmentalumis Has Entered Into A Merger Agreement With Acelyrin Inc Enhancing Its Capabilities In The Biopharmaceutical Sectorthe Company Has Approximately 145 Employees And Continues To Focus On Advancing Treatments For Immune Mediated Diseases Through Strategic Partnerships
No conferences found for this company.
| Company Name | Alumis Inc |
| Country |
United States
|
| Address | 280 East Grand Avenue South San Francisco Ca 94080 |
| Telephone | Login to View |
| Login to View |
